SHARE

According to the recently published report ‘Integrin Alpha 7 (ITGA7) – Pipeline Review, H2 2017’; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Integrin Alpha 7 (ITGA7) – Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The report ‘Integrin Alpha 7 (ITGA7) – Pipeline Review, H2 2017’ outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

Complete research report on Arterial Thrombosis- Pipeline is available at:

https://www.marketinsightsreports.com/reports/0115155407/integrin-alpha-7-itga7-pipeline-review-h2-2017

Scope:

– The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
– The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
– The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

For Any queries feel free to reach us at: https://www.marketinsightsreports.com/reports/0115155407/integrin-alpha-7-itga7-pipeline-review-h2-2017/inquiry

Reasons to buy:

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Drug Profiles : 

AAT-008, AN-3485, BBI-2000, EB-01, EB-05 , grapiprant, HPT-721, NCT-10004, pertussis [strain BPZE1] vaccine, secukinumab, SIG-1322, WOL-071007

Drug Profiles : 

BIX-01294, CM-272, EZM-8266, Small Molecules to Inhibit G9a for Breast Cancer, Small Molecules to Inhibit G9a for Oncology, TM-2115, verticillin A.

Companies Involved in Therapeutics Development are :

Domainex Ltd., Epizyme Inc.

 About Us:

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more.

For more information contact at sales@marketinsightsreports.com or call us at +1 (704) 266-3234

Connect With us On: 

https://www.linkedin.com/company/13411016/

https://www.facebook.com/marketinsightsreports/

https://twitter.com/MIRresearch